e-learning
resources
Vienna 2003
Tuesday 30.09.2003
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Thrombin-antithrombin (TAT) complexes in pulmonary hypertension
P. Jansa, M. Sidova, H. Spundova, Z. Susa, M. Aschermann (Prague, Czech Republic)
Source:
Annual Congress 2003 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
Thematic Poster Session
Number:
2928
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Jansa, M. Sidova, H. Spundova, Z. Susa, M. Aschermann (Prague, Czech Republic). Thrombin-antithrombin (TAT) complexes in pulmonary hypertension. Eur Respir J 2003; 22: Suppl. 45, 2928
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Prognoctic value of platelet factor-4 and thrombin-antithrombin complex for pulmonary hypertension among patients with idiopathic interstitial pneumonias
Source: Eur Respir J 2006; 28: Suppl. 50, 658s
Year: 2006
Platelets and pulmonary arterial hypertension (PAH)
Source: International Congress 2019 – Pulmonary hypertension: clinical
Year: 2019
Chronic thromboembolic pulmonary hypertension (CTEPH) and coagulation defects: Before and after treatment
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD).
Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases
Year: 2021
D-dimer in diagnosis of pulmonary embolization (PE)
Source: Eur Respir J 2006; 28: Suppl. 50, 46s
Year: 2006
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
Pulmonary hypertension (PH) associated with haemolysis
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
Fibrinogen Aα Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2008; 31: 736-741
Year: 2008
Epoprostenol (EPT) for acute reactivity testing (AVT) in pulmonary artery hypertension (PAH)
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004
Liver function in patients with pulmonary tuberculosis (PT) before and during the initial phase of antituberculosis treatment (ATT)
Source: Eur Respir J 2002; 20: Suppl. 38, 365s
Year: 2002
Platelet-activating factor-acetylhydrolase (PAF-AH) activity in pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2005; 26: Suppl. 49, 695s
Year: 2005
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Arterial hypertension (AH) and endothelial function (EF) in patients with COPD
Source: Annual Congress 2011 - COPD mechanisms
Year: 2011
Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008
Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 354s
Year: 2006
The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH)
vs
idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009
Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH)
Source: Eur Respir J 2003; 22: Suppl. 45, 270s
Year: 2003
6MWD in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 464s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept